Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/12/2025 | Buy → Hold | Jefferies | |
2/12/2025 | $45.00 → $17.00 | Outperform → Neutral | Mizuho |
2/12/2025 | Buy → Neutral | BTIG Research | |
2/12/2025 | Outperform → Mkt Perform | William Blair | |
7/15/2024 | $50.00 → $37.00 | Equal-Weight → Underweight | Morgan Stanley |
6/11/2024 | $46.00 | Neutral → Buy | BTIG Research |
3/11/2024 | $30.00 → $50.00 | Hold → Buy | Stifel |
12/5/2023 | Buy → Hold | Needham |
Net Sales of $313.9 Million and ICL Sales of $312.5 Million for Fiscal 2024 Impacted by Weak China Macroeconomic Conditions ICL Sales Ex. China Up 17% in Fourth Quarter and 13% in Fiscal 2024 Introduces Outlook for Fiscal 2025 Earnings Conference Call and Webcast Today at 5:00 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended December 27, 2024. The Company moved up its earnings announcement and will hold a conference call and webcast today at 5:00 p.m. Eastern to discuss its financial results, oper
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended December 27, 2024, on or about Wednesday, February 19 after the market close. "Our industry-leading EVO ICL technology and market-building initiatives supported our ability to achieve double-digit year-over-year ICL sales growth globally in fiscal 2024, with the exception of China," said Tom Frinzi, Chair of the Board and CEO of STAAR Surgical. "The pervasive and well-documented economic conditions and lower levels of consumer confidenc
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the third quarter ended September 27, 2024, on Wednesday, October 30, 2024, after the market close. Event: STAAR Surgical 3Q 2024 Financial Results Webcast Date: Wednesday, October 30, 2024 Time: 4:30 p.m. ET / 1:30 p.m. PT Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fmU0YbKB STAAR will also host an earnings webcast on Wednesday, October 30 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and op
8-K - STAAR SURGICAL CO (0000718937) (Filer)
10-K - STAAR SURGICAL CO (0000718937) (Filer)
8-K - STAAR SURGICAL CO (0000718937) (Filer)
Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of Directors, has been appointed President and CEO, effective February 26, 2025. Tom Frinzi, STAAR's current President and CEO, will remain with the Company in an advisory role through January 2026 to support the leadership transition and build upon STAAR's strong relationships in the ophthalmic community. "We are pleased to
Net Sales of $313.9 Million and ICL Sales of $312.5 Million for Fiscal 2024 Impacted by Weak China Macroeconomic Conditions ICL Sales Ex. China Up 17% in Fourth Quarter and 13% in Fiscal 2024 Introduces Outlook for Fiscal 2025 Earnings Conference Call and Webcast Today at 5:00 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended December 27, 2024. The Company moved up its earnings announcement and will hold a conference call and webcast today at 5:00 p.m. Eastern to discuss its financial results, oper
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended December 27, 2024, on or about Wednesday, February 19 after the market close. "Our industry-leading EVO ICL technology and market-building initiatives supported our ability to achieve double-digit year-over-year ICL sales growth globally in fiscal 2024, with the exception of China," said Tom Frinzi, Chair of the Board and CEO of STAAR Surgical. "The pervasive and well-documented economic conditions and lower levels of consumer confidenc
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
Jefferies downgraded STAAR Surgical from Buy to Hold
Mizuho downgraded STAAR Surgical from Outperform to Neutral and set a new price target of $17.00 from $45.00 previously
BTIG Research downgraded STAAR Surgical from Buy to Neutral
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
Stephen C. Farrell appointed CEO to succeed Tom Frinzi Elizabeth Yeu, M.D. elected Board Chair STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership transition. Stephen C. Farrell, current Lead Independent Director of the STAAR Board of Directors, has been appointed President and CEO, effective February 26, 2025. Tom Frinzi, STAAR's current President and CEO, will remain with the Company in an advisory role through January 2026 to support the leadership transition and build upon STAAR's strong relationships in the ophthalmic community. "We are pleased to
New Appointments Underscore Commitment to Driving Innovation and Industry-Leading Growth STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company's executive committee and report to Tom Frinzi, STAAR Surgical's President and CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501408389/en/Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo:
STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Directors, effective March 12, 2024. "Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry," said Aimee Weisner, Chair
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)